CD133 Description
CD133, also known as Prominin 1 in both human and rodent, is expressed in endothelial progenitor cells, neuronal stem cells, glioblastoma, glial stem cells and some normal tissues such as kidney and brain. CD133 has been used to enrich a subpopulation of highly tumorigenic cancer cells in gliomas. According to the cancer stem cell hypothesis, CD133-positive cells determine long-term tumor growth and, therefore, are
suspected to influence clinical outcome. Recent studies have determined that the
expression of CD133 correlates with patient survival in gliomas, giving credence to the current cancer stem cell hypothesis. BRCA-1 breast tumors have been shown to contain distinct CD133+ cells with cancer stem cell characteristics.